| 1 |
Global Initiative for Asthma. Global strategy for asthma management and prevention 2026[EB/OL]. 2026.
URL
|
| 2 |
Lambrecht BN, Ahmed E, Hammad H. The immunology of asthma[J]. Nature Immunology, 2025, 26(8): 1233-1245.
|
| 3 |
中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2024年版)[J]. 中华结核和呼吸杂志，2025, 48(3): 208-248.
|
| 4 |
Di Cicco ME, Peroni D, Marseglia GL, et al. Unveiling the complexities of pediatric asthma treatment: evidence, controversies, and emerging approaches[J]. Pediatric Drugs, 2025, 27(4): 393-404.
|
| 5 |
Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate[J]. Clinical Pharmacokinetics, 2013, 52(1): 37-42.
|
| 6 |
Yu YL, Ni MJ, Zheng YX, et al. Airway epithelial-targeted nanoparticle reverses asthma in inhalation therapy[J]. J Controlled Release, 2024, 367: 223-234.
|
| 7 |
Chen H, Li J. Comparative effectiveness of fixed-dose fluticasone propionate/salmeterol and budesonide/formoterol combinations in asthma: a us database analysis[J]. Chest, 2024, 166(4): A6461-A6462.
|
| 8 |
Global Initiative for Asthma. GINA 2025 pocket guide for asthma management and prevention[EB/OL]. 2025.
URL
|
| 9 |
Laforce C, Albers F, Anna Danilewicz BS, et al. As-needed albuterol-budesonide in mild asthma[J]. N E J M, 2025, 393(2): 113-124.
|
| 10 |
Richard G, Proudman W, Jillian G. Baker. A comparison of the molecular pharmacological properties of current short, long, and ultra-long-acting β2-agonists used for asthma and COPD[J]. Pharmacology Research & Perspectives, 2025, 13(5): e70154 .
|
| 11 |
刘平香，董利民，沈湘波. 氟替美维吸入粉雾剂联合小剂量阿奇霉素用于老年AECOPD患者肺康复治疗中的临床观察[J]. 中国医学创新，2024, 21(9): 129-133，5.
|
| 12 |
Singh D, Virchow JC, Canonica GW, et al. Extrafine triple therapy in patients with asthma and persistent airflow limitation[J]. Eur Respir J, 2020, 56(3): 2000476.
|
| 13 |
Louis-Philippe B, Carl A, Guy B, et al. Baseline characteristics and ICS/LAMA/LABA response in asthma: analyses from the CAPTAIN study[J]. J Allergy Clin Immunol Pract, 2024, 12(5): 1244-1253.e8.
|
| 14 |
中华医学会呼吸病学分会. 支气管哮喘防治指南(2024年版)[J]. 中华结核和呼吸杂志，2025, 48(3): 208-248.
|
| 15 |
Cai X, Rong R, Huang Y, et al. Effects of theophylline combined with inhaled corticosteroids on patients with moderate and severe asthma and changes of T lymphocyte subsets in peripheral blood[J]. Cent Eur J Immunol, 2023, 48(2): 135-143.
|
| 16 |
FDA. Approval Letter: Depemokimab-abgi (Exdensur)[EB/OL]. December 2025.
URL
|
| 17 |
Bleecker E, Blaiss M, Jacob-Nara J. Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study[J]. JACI, 2024, 154(6): 1500-1510.
|
| 18 |
中华医学会儿科学分会呼吸学组. 儿童支气管哮喘诊断与防治指南(2025) [J]. 中华儿科杂志，2025, 63(4): 324-337.
|
| 19 |
Stephen TH, Ratko D, Thomas C, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy[J]. JACI, 2023, 152(6). 10.1016/j.jaci.2023.10.014
|
| 20 |
张翼，韩嘉伦，于晓佳，等. 奥马珠单抗治疗中重度过敏性哮喘的疗效及安全性评价[J]. 临床药物治疗杂志，2023, 21(9): 51-55.
|
| 21 |
Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma[J]. N E JM, 2021, 384(19): 1800-1809.
|
| 22 |
Wechsler ME, Brusselle G, Virchow JC, et al. Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies[J]. Eur Respir J, 2024, 64(6): 2400316.
|
| 23 |
Yang X, Wang L, Huang K. Efficacy and safety of tezepelumab in adults with severe, uncontrolled asthma in asia: results from the phase 3 DIRECTION study[J]. J Allergy Clin Immunol Pract, 2025, 13(11): 3011-3020.e9.
|
| 24 |
Balasubramanyam S, George EK, Wang E. Precision medicine and choosing a biologic in asthma: understanding the current state of knowledge for predictors of response and clinical remission[J]. Curr Opin Allergy Clin Immunol, 2025, 25(1): 66-74.
|
| 25 |
Liu T, Woodruff PG, Zhou X. Advances in non type 2 severe asthma：from molecular insights to novel treatment strategies[J]. Eur Respir J, 2024, 64(2): 2300826.
|
| 26 |
Tokareva Kate, Reid Pankti, Yang Victor, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors？[J]. Expert Rev Clin Immunol, 2023, 19(11): 1385-1397.
|
| 27 |
Taylor PC, Choy E, Baraliakos X, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases[J]. Rheumatology (Oxford), 2024, 63(2): 298-308.
|
| 28 |
国家皮肤与免疫疾病临床医学研究中心(北京协和医院). Janus激酶抑制剂治疗免疫介导炎症性疾病中国专家共识[J]. 中华内科杂志，2025, 64(12): 1187-1210.
|
| 29 |
Anne ED, Loretta GQ, Ravi K, et al. Roflumilast may increase risk of exacerbations when used to treat poorly controlled asthma in people with obesity[J]. Ann Am Thorac Soc, 2023, 20(2): 206-214.
|
| 30 |
Goonathilake MR, Waqar S, George S, et al. Can phosphodiesterase 4 inhibitor therapy be used in respiratory diseases other than COPD？[J]. Cureus, 2022, 14(7): e27132.
|
| 31 |
陈华萍，陈晓龙，胡明冬. 难治性哮喘的发病机制及诊治进展[J/OL]. 中华肺部疾病杂志(电子版) 2024, 17(1): 144-147.
|
| 32 |
Papi A, Kershaw A. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials[J]. Lancet Respiratory Medicine, 2026, 14(4) . 10.1016/S2213-2600(25)00457-6.
|
| 33 |
Global Initiative for Asthma. GINA 2025 Report: Triple Therapy Recommendations[EB/OL]. 2025.
URL
|
| 34 |
Francesco M, Claudio S, Carlo L, et al. Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach[J]. Drugs in Context, 2025, 14: 2025-7-2
|
| 35 |
Kim SH. Biologic therapies in severe asthma and EGPA: targeted therapy and personalized care[J]. Tuberc Respir Dis, 2026, 89(1): 1-9.
|
| 36 |
Dennis T, Yuto H, Peter GG, et al. Diagnosis and treatment options for t2-low asthma[J]. J Allergy Clin Immunol Pract, 2025, 13(7): 1527-1539.
|
| 37 |
Neunie OAM, Rabbani W, Baker D, et al. Immunogenicity of biologics used in the treatment of asthma[J]. Hum Antibodies, 2024, 32(3): 121-128.
|
| 38 |
中华医学会儿科学分会呼吸学组. 儿童支气管哮喘诊断与防治指南(2025)[J]. 中华儿科杂志，2025, 63(4): 324-337.
|
| 39 |
Alessandra T, Stanley JS, Katherine NC. Emerging systemic treatments for asthma and allergic diseases: new tricks, same dog？[J]. J Allergy Clin Immunol Pract, 2026, 14(2): 325-335.
|
| 40 |
Bousquet J, Wenzel SE. Precision medicine in asthma: phenotypes, endotypes and biomarkers[J]. J Allergy Clin Immunol , 2024, 153(3): 679-692.
|